Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 98

Results For "MEA"

1156 News Found

DCGI approves Phase 3 clinical trial of Stempeucel to treat Covid-19 patients
Biotech | January 18, 2022

DCGI approves Phase 3 clinical trial of Stempeucel to treat Covid-19 patients

The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)


U.S. FDA approves treatment to control pain in cats with osteoarthritis
Drug Approval | January 14, 2022

U.S. FDA approves treatment to control pain in cats with osteoarthritis

It is the first monoclonal antibody drug for use in any animal species


Normalised quarter with impending margin pressure: ICICI Direct
News | January 13, 2022

Normalised quarter with impending margin pressure: ICICI Direct

ICICI Direct gives a preview on the earnings narrative for Q3FY22


BioGenex RT-PCR Kit detects all Covid variants in half the time
Medical Device | January 13, 2022

BioGenex RT-PCR Kit detects all Covid variants in half the time

This test analyses samples in VTM directly without the need for RNA extraction step


Outlook for the Indian Pharma Industry remains stable for this year
Opinion | January 13, 2022

Outlook for the Indian Pharma Industry remains stable for this year

The stability is led by healthy demand in the domestic and emerging markets


Sinocompound and InCatT launch new Catalyst Screening Service
Biotech | January 12, 2022

Sinocompound and InCatT launch new Catalyst Screening Service

This service benefits pharmaceutical and fine chemical companies looking to optimise their reactions


ABL Bio collaborates with SANOFI for Parkinson’s antibody
Biotech | January 12, 2022

ABL Bio collaborates with SANOFI for Parkinson’s antibody

ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease


We achieved  40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer
Biotech | January 11, 2022

Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer

First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC


We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry